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Abstract
PURPOSE: To evaluate the safety and efficacy of topical recombinant human nerve growth factor (rhNGF) for treating
moderate-to-severe neurotrophic keratitis (NK), a rare degenerative corneal disease resulting from loss of corneal
innervation. DESIGN: Phase II multicenter, randomized, double-masked, vehicle-controlled trial. PARTICIPANTS:
Patients with stage II (moderate) or stage III (severe) NK in one eye. METHODS: The REPARO Phase II study
assessed safety and efficacy in 156 patients randomized 1:1:1 to rhNGF 10 μg/ml, 20 μg/ml, or vehicle. Treatment
was administered 6 drops per day for 8 weeks. Patients then entered a 48- or 56-week follow-up period. Safety was
assessed in all patients who received study drug, while efficacy was by intention to treat. MAIN OUTCOME
MEASURES: Corneal healing (defined as <0.5 mm maximum diameter of fluorescein staining in the lesion area) was
assessed in clinical pictures by masked central readers at week 4 (primary efficacy endpoint) and week 8 (key
secondary endpoint) of controlled treatment. Corneal healing was also assessed post hoc by masked central readers
using a more conservative measure (0 mm staining in the lesion area and no other persistent staining). RESULTS: At
week 4 (primary endpoint), 19.6% of vehicle-treated patients achieved corneal healing (<0.5 mm lesion staining), vs.
54.9% receiving rhNGF 10 μg/ml (+35.3%; 97.06% confidence interval [CI] 15.88–54.71; P<0.001) and 58.0%
receiving rhNGF 20 μg/ml (+38.4%; 97.06% CI 18.96–57.83; P<0.001). At week 8 (key secondary endpoint), 43.1% of
vehicle-treated patients achieved <0.5 mm lesion staining, vs. 74.5% receiving rhNGF 10 μg/ml (+31.4%; 97.06% CI
11.25–51.49; P<0.001) and 74.0% receiving rhNGF 20 μg/ml (+30.9%; 97.06% CI 10.60–51.13, P<0.002). Post hoc
analysis of corneal healing by the more conservative measure (0 mm lesion staining and no other persistent staining)
maintained statistically significant differences between rhNGF and vehicle at weeks 4 and 8. Over 96% of patients
healed after controlled rhNGF treatment remained recurrence-free during follow-up. Treatment with rhNGF was well
tolerated; adverse effects were mostly local, mild, and transient. CONCLUSIONS: Topical rhNGF is safe, and more
effective than vehicle in promoting healing of moderate-to-severe NK.
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559 Abstract (350 words)60 PURPOSE: To evaluate the safety and efficacy of topical recombinant human nerve growth 61 factor (rhNGF) for treating moderate-to-severe neurotrophic keratitis (NK), a rare 62 degenerative corneal disease resulting from loss of corneal innervation.63 DESIGN: Phase II multicenter, randomized, double-masked, vehicle-controlled trial.64 PARTICIPANTS: Patients with stage II (moderate) or stage III (severe) NK in one eye.65 METHODS: The REPARO Phase II study assessed safety and efficacy in 156 patients 66 randomized 1:1:1 to rhNGF 10 μg/ml, 20 μg/ml, or vehicle. Treatment was administered 6 67 drops per day for 8 weeks. Patients then entered a 48- or 56-week follow-up period. Safety 68 was assessed in all patients who received study drug, while efficacy was by intention to 69 treat.70 MAIN OUTCOME MEASURES: Corneal healing (defined as <0.5 mm maximum diameter of 71 fluorescein staining in the lesion area) was assessed in clinical pictures by masked central 72 readers at week 4 (primary efficacy endpoint) and week 8 (key secondary endpoint) of 73 controlled treatment. Corneal healing was also assessed post hoc by masked central 74 readers using a more conservative measure (0 mm staining in the lesion area and no other 75 persistent staining).76 RESULTS: At week 4 (primary endpoint), 19.6% of vehicle-treated patients achieved 77 corneal healing (<0.5 mm lesion staining), vs. 54.9% receiving rhNGF 10 μg/ml (+35.3%; 78 97.06% confidence interval [CI] 15.88–54.71; P<0.001) and 58.0% receiving rhNGF 20 79 μg/ml (+38.4%; 97.06% CI 18.96–57.83; P<0.001). At week 8 (key secondary endpoint), 80 43.1% of vehicle-treated patients achieved <0.5 mm lesion staining, vs. 74.5% receiving 81 rhNGF 10 μg/ml (+31.4%; 97.06% CI 11.25–51.49; P<0.001) and 74.0% receiving rhNGF 
682 20 μg/ml (+30.9%; 97.06% CI 10.60–51.13, P<0.002). Post hoc analysis of corneal healing 83 by the more conservative measure (0 mm lesion staining and no other persistent staining) 84 maintained statistically significant differences between rhNGF and vehicle at weeks 4 and 85 8. Over 96% of patients healed after controlled rhNGF treatment remained recurrence-free 86 during follow-up. Treatment with rhNGF was well tolerated; adverse effects were mostly 87 local, mild, and transient.88 CONCLUSIONS: Topical rhNGF is safe, and more effective than vehicle in promoting healing 89 of moderate-to-severe NK.90
791 INTRODUCTION92 With approximately 7000 nerve endings/mm2, the cornea is the most densely innervated 93 tissue in humans.1 Corneal nerves (deriving from the trigeminal ganglion) help maintain 94 transparency in this avascular tissue and participate in ocular surface homeostasis by 95 producing neurotrophins and facilitating sensory-dependent corneal and tearing reflexes.1, 96 2 Trigeminal nerve damage may cause neurotrophic keratitis/keratopathy (NK) with 97 partial or total loss of corneal sensation, leading to visual impairment and potentially 98 permanent blindness. NK is a rare disease (estimated prevalence: 1.6–4.2 cases per 99 10,000)3, 4 with various underlying etiologies (most commonly herpetic infections and 100 ocular or neurological surgeries) that impair corneal innervation.5, 6 NK diagnosis, 101 prognosis, and treatment (reviewed elsewhere)3, 6 are based on disease severity, which is 102 classified broadly into three stages.7 Briefly, stage 1 (mild) NK exhibits ocular surface 103 irregularity and reduced vision. Stage 2 (moderate) NK exhibits a nonhealing persistent 104 epithelial defect (PED), and stage 3 (severe) NK exhibits corneal ulceration involving sub-105 epithelial (stromal) tissue, which may progress to corneal perforation. All disease stages 106 cause some vision loss; however, if untreated, moderate NK progresses to severe disease 107 with associated risks of profound vision loss due to scarring and corneal perforation. 108 Conventional therapy for stage 1 aims to prevent epithelial breakdown, generally by 109 administering preservative-free artificial tears and discontinuing toxic topical medications. 110 Stage 2/3 therapies aim to facilitate corneal healing and prevent corneal thinning (which 111 may lead to perforation); these include surgeries and procedures (e.g., tarsorrhaphy, 112 botulinum-induced ptosis, conjunctival flap, amniotic membrane transplantation) to 113 restore ocular surface integrity, but potentially sacrificing vision and cosmesis.
8114115 Strong evidence supports the treatment of NK with neurotrophic factors.8 Nerve growth 116 factor (NGF) has demonstrated important roles in maintaining corneal homeostasis in 117 vitro, ex vivo, and in animal models.9, 10 NGF is highly conserved among vertebrates,11 and 118 small uncontrolled, open-label studies with murine NGF (mNGF) produced promising 119 results for the treatment of corneal neurotrophic ulcers.12, 13 Confirmation of results 120 obtained with mNGF have been highly anticipated14; however, nearly two decades passed 121 with no approved treatments for NK, and no NGF-based treatments available for any 122 indication. For NK therapies in general, clinical development has been hindered by the 123 paucity of adequately sized and rigorously designed studies; indeed, only one randomized 124 controlled trial of NK patients exists in the published literature to date, and the 125 investigative treatment (topical fibronectin ophthalmic solution) was not superior to 126 placebo for healing PEDs.15 Thus, the natural history of NK is not completely understood, 127 and approved treatments are not available for use as comparators for further studies. For 128 NGF in particular, translational development has been mired by its complex tertiary 129 structure, which complicates the manufacturing of recombinant human NGF (rhNGF) 130 suitable for clinical use. To this end, we developed an E. coli-derived rhNGF formulation for 131 topical ophthalmic use and demonstrated it to be safe and well tolerated in phase I 132 randomized, double-masked, vehicle-controlled studies in healthy volunteers16 and in NK 133 patients.17 Here, we report phase II study results of topical rhNGF treatment for moderate-134 to-severe NK.135
9136 METHODS137138 Clinical Trial Design139140 REPARO (Latin, “repair”) was a phase I/II, double-masked, randomized, multicenter, 141 vehicle-controlled, parallel group study, which was designed to evaluate the safety and 142 efficacy of rhNGF eye drops (10 or 20 µg/ml, 6 drops/day for 8 weeks) in patients with 143 stage 2 or 3 NK. Phase I assessed safety in 18 patients to support proceeding to phase II, 144 and was conducted, analyzed, and reported separately.17 Phase II randomized 156 patients 145 1:1:1 to rhNGF 10 µg/ml, rhNGF 20 µg/ml, or vehicle for an 8-week controlled treatment 146 period. Follow-up duration (48 or 56 weeks) was determined by baseline group 147 assignment and corneal healing status during controlled treatment. For vehicle-treated 148 patients, baseline randomization included the possibility of secondary rhNGF treatment 149 (10 or 20 µg/ml) in the event of treatment failure during the 8-week controlled treatment 150 period, pre-defined as failure to achieve corneal healing, recurrence of NK after healing, or 151 deterioration (lesion size increase of ≥1mm; best corrected distance visual acuity [BCDVA] 152 decrease of >5 Early Treatment Diabetic Retinopathy Study [ETDRS] letters; progression to 153 corneal melting/perforation; or onset of infection). This patient subset received 8 weeks of 154 uncontrolled treatment before continuing follow-up (total follow-up: 56 weeks).155156 The phase II study design is diagrammed in Figure 1. The REPARO study group is listed in 157 Appendix 1, and the trial was registered at ClinicalTrials.gov (identifier NCT01756456).158
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159 Patients160161 Patients (≥18 years of age) with NK were diagnosed with stage 2 (PED) or stage 3 (corneal 162 ulcer) using published criteria.7 The main inclusion criteria were: evidence of decreased 163 corneal sensitivity within the corneal lesion and ≥1 corneal quadrant outside the lesion; 164 BCDVA score of ≤75 ETDRS letters (≥ +0.2 logMAR, ≤ 20/32 Snellen or ≤ 0.625 decimal 165 fraction) in the affected eye; and no objective clinical evidence of improvement of the PED 166 or corneal ulcer within 2 weeks prior to study enrollment. The main exclusion criteria were 167 stage 2/3 NK affecting both eyes; active ocular infection or inflammation unrelated to NK; 168 and other ocular disease or severe vision loss in the affected eye. For complete 169 inclusion/exclusion criteria, see Appendix 2 (available at www.aaojournal.org).170171 Efficacy Assessments172173 The primary efficacy variable was corneal healing, defined as <0.5 mm fluorescein staining 174 (the lower limit of reliable slit-lamp assessment) in the lesion area, assessed in clinical 175 pictures by masked central readers as a yes/no binary variable at week 4 (primary 176 endpoint) and week 8 (prespecified secondary endpoint). Other secondary variables 177 included visual acuity (BCDVA measured in ETDRS letters); corneal sensitivity measured 178 using the Cochet-Bonnet aesthesiometer (CBA); and duration of corneal healing through 179 follow-up.180181 Exploratory efficacy variables included reflex tearing (Schirmer test wetting distance after 
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182 5 minutes); time to onset of healing (>20% reduction in maximum diameter of the corneal 183 lesion from baseline); and time to corneal healing (<0.5 mm lesion staining) during the 184 controlled/uncontrolled treatment periods. Post hoc efficacy variables included change in 185 lesion size, and the primary endpoint of corneal healing reassessed more conservatively as 186 0 mm lesion staining and no other persistent staining outside of the lesion.187188 Safety Assessments189190 The primary safety variable was incidence of adverse events (AEs). Ocular tolerability was 191 recorded by patients on a visual analogue scale (VAS) from 0–100 mm (0 = no symptoms; 192 100 = worst possible discomfort) for each of 7 different symptoms: foreign body sensation, 193 burning/stinging, itching, ocular pain, sticky feeling, blurred vision, and photophobia. An 194 overall VAS score was calculated as the mean of individual symptom scores. Other safety 195 parameters included visual acuity (BCDVA measured in ETDRS letters), intraocular 196 pressure (IOP), dilated fundus ophthalmoscopy, vital signs, hematology, and clinical 197 chemistry.198199 Pharmacokinetics and Immunogenicity Assessments200201 Blood samples were collected for pharmacokinetics (PK) profiling and immunogenicity 202 assessments (anti-NGF antibody shifts from baseline to post-baseline), performed using 203 enzyme-linked immunosorbent assay (ELISA) as described previously.16204
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205 Masking and Statistical Analysis206207 Patients, investigators, and site/sponsor staff were masked to primary randomized 208 treatment and to the dosage of randomized secondary treatment. Indistinguishable kits for 209 dispensing rhNGF or vehicle were randomly assigned according to numbers generated by 210 Statistical Analysis System programmers not directly involved in study analysis. The 211 sponsor was not involved in efficacy data collection for masked central analysis. 212 Assessments by the central reading center were masked to treatment assignment and 213 duration. Unmasking was restricted to final statistical analysis (after database lock) and 214 medical emergencies, including NK recurrence or deterioration. A clinical research 215 organization (CRO) maintained the masked database and performed statistical analyses.216217 Based on the only published randomized controlled trial of NK15 and uncontrolled studies 218 of mNGF-treated NK patients,12, 13 60% of rhNGF-treated patients were estimated to 219 achieve <0.5 mm lesion staining at 4 weeks (vs. 30% in vehicle-treated patients). Although 220 the study’s exploratory nature did not warrant adjustment for multiple comparisons, 2-221 sided significance of chi-square testing was corrected according to Pocock,18 yielding a 222 97.06% confidence interval (CI) for the primary efficacy endpoint of corneal healing. 223 According to this methodology, phase II required 141 evaluable patients to have 80% 224 power to detect this difference in the primary efficacy variable, and 156 patients assuming 225 10–20% dropout. Efficacy analyses were performed on intention-to-treat (ITT) 226 populations, with missing data imputed using post-baseline last observation carried 227 forward (LOCF). Also conducted were observed-case and sensitivity analyses (missing 
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228 post-baseline observations imputed as failures, and by multiple imputation methods MI 229 and MIANALYZE). 230231 For binary secondary and exploratory efficacy endpoints, two-sided significance was set at 232 0.05. Change in BCDVA score from baseline to week 8 was analyzed by an analysis of 233 covariance (ANCOVA) model using treatment group and baseline BCDVA score. Mixed 234 effects repeated measures models using treatment, visit, and baseline measurements were 235 used to assess changes in lesion size (maximum dimension) and reflex tearing (Schirmer 236 test wetting distance) from baseline to week 4 and week 8. The time to onset of healing 237 (>20% reduction in maximum diameter of the corneal lesion from baseline) and corneal 238 healing (<0.5 mm maximum diameter of fluorescein staining) were analyzed using Kaplan-239 Meier methods and the log-rank test (for the controlled treatment period) and descriptive 240 statistics (for the uncontrolled treatment period). Data collected during follow-up were 241 also analyzed using descriptive statistics.242243 Study Oversight244245 Approval was obtained for the study protocol, amendments, and study-related documents 246 (including informed consent) from the institutional review board (IRB) of Sapienza 247 University of Rome and an independent ethics committee (IEC) from each country with one 248 or more participating sites (listed in Appendix 1). The study complied with the Declaration 249 of Helsinki, relevant parts of Code of Federal Regulations Title 21, and Good Clinical 250 Practice (GCP)/Good Laboratory Practice (GLP) guidelines. Written informed consent was 
14
251 obtained prior to study-related procedures. Compliance was assessed at each visit and 252 verified by study monitors during onsite visits.253
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254 RESULTS255256 Patients and Treatment257258 REPARO investigators (Appendix 1) represented 39 sites in 9 European countries 259 (Belgium, France, Germany, Hungary, Italy, Poland, Portugal, Spain, and the United 260 Kingdom); 32 sites in 6 countries enrolled ≥1 patient. Figure 1 provides an overview of 261 patient disposition (including reasons for withdrawal). Of 186 patients screened January 262 2013–May 2015, 174 were enrolled—18 in phase I,17 and 156 in phase II. Patient 263 demographics and baseline characteristics were well balanced in the REPARO phase II 264 study, with no clinically notable differences between treatment groups (Table 1). 265 Consistent with published literature,5, 6, 13, 19 common underlying etiologies included 266 herpetic eye disease (44 patients) and ocular or neurological surgery (21 patients each). 267 Prior treatments for NK (most commonly artificial tears/gels/ointments and topical 268 antibiotics) are shown in Appendix 3 (available at www.aaojournal.org).269270 Efficacy Outcomes271272 Table 2 summarizes efficacy analyses at weeks 4 and 8. Corneal healing (<0.5 mm lesion 273 staining) was achieved at week 4 (primary endpoint) in 19.6% of vehicle-treated patients 274 vs. 54.9% receiving rhNGF 10 μg/ml (+35.3%; 97.06% CI 15.88–54.71; P<0.001) and 275 58.0% receiving rhNGF 20 μg/ml (+38.4%; 97.06% CI 18.96–57.83; P<0.001). Corneal 276 healing at week 8 (key secondary endpoint) was achieved in 43.1% of vehicle-treated 
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277 patients vs. 74.5% receiving rhNGF 10 μg/ml (+31.4%; 97.06% CI 11.25–51.49; P<0.001) 278 and 74.0% receiving rhNGF 20 μg/ml (+30.9%; 97.06% CI 10.60–51.13; P<0.002). Table 3 279 summarizes the post hoc reanalysis of corneal healing using the more-conservative 280 definition (0 mm lesion staining and no other persistent staining). This confirmed 281 statistically significant differences between rhNGF and vehicle, with consistently higher 282 percentages healed in the rhNGF 20 μg/ml group at both week 4 and week 8. Observed-283 case, worst-case (missing post-baseline observations imputed as failures), and multiple 284 imputation analyses produced similar results (not shown). Differences between rhNGF 285 groups were not statistically significant.286287 Figure 2A shows representative images of corneal fluorescein staining at baseline through 288 week 8. Lesion size changes from baseline (determined by the reading center) were 289 analyzed post hoc for clinically significant differences between treatments (Figure 2B). At 290 week 4, least squares mean (LSmean) lesion size change from baseline was -49.8% with 291 rhNGF 20 µg/ml, -39.5% with rhNGF 10 µg/ml, and -8.9% with vehicle. At week 8, lesion 292 size change was -76.0% with rhNGF 20 µg/ml, -58.4% with rhNGF 10 µg/ml, and -26.2% 293 with vehicle. Overall, rhNGF-treated patients exhibited greater (but statistically 294 nonsignificant) lesion size reductions from baseline vs. vehicle-treated patients, trending 295 towards significance in rhNGF 20 μg/ml vs. vehicle at week 8 (p=0.102, 95% CI -109.61–296 9.98).297298 Visual acuity outcomes were assessed as changes from baseline to week 8. As shown in 299 Figure 3, compared to vehicle-treated patients, LSmean change in BCDVA score (ETDRS 
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300 letters) from baseline to week 8 was significantly different in patients receiving rhNGF 10 301 μg/ml (p=0.022) but not those receiving rhNGF 20 μg/ml (p=0.213). However, the 302 difference between rhNGF doses was not significant (p=0.305). BCDVA assessed as gain of 303 15 ETDRS letters (yes/no) from baseline to week 8 produced similar results (Table 4). 304 Compared to vehicle, 15-letter gains were achieved by more patients receiving rhNGF 10 305 μg/ml (+27.5%; 95% CI: 8.33–46.67; p=0.008) and rhNGF 20 μg/ml (+19%; 95% CI: 0.91–306 38.83; p=0.068), with no statistically significant difference between rhNGF doses 307 (p=0.421).308309 Corneal sensitivity during the controlled treatment period was measured directly in the 310 corneal lesion and outside quadrants using the CBA as secondary efficacy variable, and 311 indirectly by Schirmer testing of reflex tearing as an exploratory variable. Compared to 312 vehicle, more patients receiving rhNGF 10 or 20 μg/ml exhibited improvement in corneal 313 sensitivity (cm) from baseline to weeks 4 and 8, but the differences between treatment 314 groups were not significant (Table 5, available online at www.aaojournal.org).  Figure 4 315 (available at www.aaojournal.org) shows results of Schirmer tests of reflex tearing. LSmean 316 change from baseline was greater in the rhNGF-treated groups compared to those receiving 317 vehicle, with differences reaching statistical significance between rhNGF 10 μg/ml and 318 vehicle groups at week 4 (p=0.047) and week 8 (p=0.010). Comparisons between patients 319 receiving rhNGF 20 μg/ml and vehicle were not significant at week 4 (p=0.234) or week 8 320 (p=0.201). However, comparisons between rhNGF doses were also not significant at either 321 week 4 (p=0.442) or week 8 (p=0.191).322
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323 Figure 5 illustrates exploratory Kaplan-Meier analyses of time-to-event variables for the 324 controlled treatment period. The median time to onset of healing (20% reduction in 325 maximum lesion diameter from baseline), which was 14 days in patients receiving vehicle 326 (95% CI 14–28), compared to 8 days in patients receiving rhNGF 10 μg/ml (95% CI 7–14; 327 p=0.002) and 14 days in patients receiving rhNGF 20 μg/ml (95% CI 7–14; p=0.015). For 328 time to corneal healing (<0.5 mm lesion staining), median time was 56 days (95% CI 42–329 not estimable) in patients receiving vehicle, compared to 29 days in patients receiving 330 rhNGF 10 μg/ml (95% CI 20–55; p=0.002) and 28 days in patients receiving rhNGF 20 331 μg/ml (95% CI 19–55; p=0.002).332333 Follow-up data (not powered for efficacy analyses) are presented using descriptive 334 statistics. Of patients receiving vehicle during 8-week controlled treatment, 23 experienced 335 treatment failure (failure to achieve corneal healing, recurrence of NK after healing, or 336 deterioration) and entered the 56-week follow-up period, which included 8 weeks of 337 uncontrolled rhNGF treatment (see Figure 1). Per a secondary baseline randomization 338 scheme, 10 patients received 10 µg/ml rhNGF, and 13 received 20 µg/ml rhNGF. At the end 339 of uncontrolled treatment, corneal healing (<0.5 mm lesion staining, assessed by the 340 investigator) was achieved in 3/10 (30%) patients receiving 10 µg/ml rhNGF, and 8/13 341 (61.5%) patients receiving 20 µg/ml rhNGF. Figure 6 (available at www.aaojournal.org) 342 shows Kaplan-Meier plots of time-to-event variables for the 8-week uncontrolled 343 treatment portion of the 56-week follow-up period. Onset of healing was assessed as 20% 344 reduction in maximum lesion diameter from the last measurement of the controlled 345 treatment period. Median time to onset of healing was 14.5 days (range, 7–55) in the 10 
19
346 µg/ml rhNGF group, and 7 days (range, 7–42) in the 20 µg/ml rhNGF group. Median time to 347 corneal healing (<0.5 mm lesion staining) in the 10 µg/ml rhNGF group was 15 days (range, 348 14–27) and 21 days (range, 7–42) in the 20 µg/ml rhNGF group.349350 Of patients who achieved corneal healing (<0.5 mm lesion staining) and completed follow-351 up, very few experienced recurrence of the PED or corneal ulcer. Of those who healed after 352 controlled treatment and completed 48-week follow-up, recurrence was experienced by 353 1/20 patients in the vehicle group (4.8%), 1/27 patients in the rhNGF 10 μg/ml group 354 (3.6%), and 1/28 patients in the rhNGF 20 μg/ml group (3.4%). Of patients healed after 355 uncontrolled treatment and completed 56-week follow-up, recurrence was experienced by 356 0/4 patients in the rhNGF 10 μg/ml group, and 2/6 (33%) patients in the rhNGF 20 μg/ml 357 group.358359 Safety Outcomes360361 Table 6 summarizes TAEs during controlled treatment, which occurred in 25 patients: 6 362 (11.5%) receiving rhNGF 10 μg/ml, 9 (17.3%) receiving rhNGF 20 μg/ml, and 10 (19.2%) 363 receiving vehicle. Two patients receiving rhNGF 10 μg/ml, 9 receiving rhNGF 20 μg/ml, and 364 4 receiving vehicle experienced AEs leading to discontinuation of study treatment. 365 Additional phase II safety results (TAEs during uncontrolled treatment and follow-up 366 periods) are presented in Appendix 4.367
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368 Overall, 17 patients (10.9%) experienced serious AEs (SAEs) during controlled treatment: 369 3 receiving rhNGF 10 μg/ml, 9 receiving rhNGF 20 μg/ml, and 5 receiving vehicle. No SAEs 370 were considered related to study treatment.371372 Changes from baseline VAS scores were analyzed by repeated measures ANCOVA 373 (controlled treatment period) or descriptive statistics (follow-up period). Decreases in VAS 374 scores were observed in all groups, indicating improvement in ocular tolerability, but 375 differences between groups were not statistically significant for the controlled treatment 376 period or otherwise noteworthy during follow-up.377378 Patients whose NK worsened during the study were discontinued (and respective 379 treatments unmasked) per protocol. Of vehicle-treated patients, 12 experienced 380 deterioration (2 at week 4, 4 at week 6, 6 at week 8), vs. 4 receiving rhNGF 10 μg/ml (1 at 381 week 4, 1 at week 6, 2 at week 8) and 4 receiving rhNGF 20 μg/ml (1 at week 4, none at 382 week 6, 3 at week 8).383384 Eight deaths were reported during the study: 2 during controlled treatment (1 receiving 385 rhNGF 10 µg/ml, 1 receiving rhNGF 20 µg/ml) and 6 during follow-up (4 patients in the 386 rhNGF 10 μg/ml group, and 1 each in the 20 μg/ml and vehicle groups). All events leading 387 to death (detailed in Appendix 4) were considered unrelated to study treatment.388389
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390 Pharmacokinetics and Immunogenicity391392 As shown in Figure 7 (available at www.aaojournal.org), only 5 patients (3 receiving rhNGF 393 10 μg/ml, 2 receiving rhNGF 20 μg/ml) had NGF concentrations above the lower limit of 394 quantification (LLQ) of 32.000 pg/mL at any time point. Consistent with phase I studies of 395 rhNGF,16, 17 these results likely represent individual fluctuations of endogenous NGF 396 independent of study treatment. No anti-NGF antibodies were detected at any time point 397 during controlled/uncontrolled treatment periods or follow-up. 398
399 DISCUSSION400401 This study demonstrated that topical rhNGF safely and effectively improves corneal 402 epithelial integrity in moderate-to-severe NK, confirming results achieved using mNGF.12, 13 403 While previous reports demonstrated clinical effectiveness of mNGF 200 µg/ml,12, 13 404 preclinical pharmacology tests demonstrated higher potency of E. coli-derived rhNGF vs. 405 mNGF—notably, higher affinity for human TrkA (high-affinity NGF receptor) and ~10-fold 406 potency in inducing proliferation of human TF1 cells expressing TrkA (unpublished data). 407 Thus, rhNGF 20 µg/ml was selected as the equivalent therapeutic dose, and 10 µg/ml 408 (lowest concentration compatible with analytical and manufacturing requirements) for 409 dose-response purposes. Both rhNGF doses demonstrated robust efficacy results of corneal 410 healing after 4–8 weeks of treatment. Healing was maintained through follow-up for over 411 96% of rhNGF-treated patients.412
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413 The use of intense topical lubricants and close follow-up in vehicle-treated patients shows 414 the natural course of NK using this conservative treatment approach. A subset of patients 415 receiving constant lubrication with vehicle for up to 8 weeks demonstrated epithelial 416 regrowth and closure of an NK lesion; however, lubrication alone may have a higher risk of 417 disease progression and persistence of a small corneal lesion (<0.5 mm), which may pose a 418 risk of complications (e.g., superinfection and a relapse to more-severe NK). Since healthy 419 corneas may demonstrate some degree of corneal staining,20 we compared two different 420 definitions of corneal healing. Our results suggest that the more-conservative measure of 421 corneal healing (0 mm lesion staining and no other persistent staining) is more reliable 422 than the conventional measure (<0.5 mm lesion staining) for evaluating corneal healing. 423 Although both measures produced consistent results, the more-conservative assessment 424 showed more consistent differences between rhNGF and vehicle, allowing more definitive 425 discrimination of treatment effect.426427 Clinical efficacy of topical rhNGF for treating NK was also supported by improvement on 428 other clinically relevant endpoints, including corneal lesion size, time to corneal healing (or 429 onset of healing) , BCDVA, corneal sensitivity measured by CBA, and reflex tearing (which 430 may also reflect corneal sensitivity not detectable by CBA). Although we did not observe 431 statistically significant differences between both rhNGF doses and vehicle in these 432 variables at every time point, the sample size was based on the dichotomous (yes/no) 433 primary endpoint and not powered to detect small but clinically significant differences in 434 secondary, exploratory, or post hoc variables. To this point, the rhNGF 10 μg/ml group (but 435 not the rhNGF 20 μg/ml group) exhibited statistically significant differences compared to 
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436 the vehicle group in some secondary endpoints (such as visual acuity and reflex tearing); 437 however, in the same endpoints, differences between rhNGF doses did not reach statistical 438 significance. Thus, it is difficult to draw conclusions on dose responsiveness. Nonetheless, 439 patients receiving rhNGF generally had better trends of improvement for most efficacy 440 endpoints vs. patients receiving vehicle.441442 Of note, visual acuity was assessed as secondary efficacy endpoint, even though it does not 443 necessarily reflect NK severity or healing status. For example, in stage 2 NK, absence of the 444 epithelium may have little or no impact on vision, while re-epithelialization in the 445 central/paracentral cornea can cause optical aberrations (and hence reduced vision). 446 Figure 2a illustrates this latter point; it would not be surprising that this patient still had 447 reduced vision after 8 weeks of controlled rhNGF 20 μg/ml treatment, despite achieving 448 corneal healing with 0 mm lesion staining and no other persistent staining.449450 No safety concerns arose; most AEs were ocular, mild, transient, and did not require 451 discontinuing or corrective treatments. The predominant TAE was eye pain; others 452 included abnormal sensation in the eye, excess lacrimation, photophobia, eyelid pain and 453 eye/eyelid irritation, which may reflect therapeutic actions of rhNGF and normal healing. 454 Indeed, restoring corneal innervation and sensitivity (which, in turn, will promote corneal 455 healing) can be associated with increased ocular surface symptomatology. No 456 immunogenicity to NGF was detected in this study; furthermore, consistent with phase I 457 results,16, 17 most patients had undetectable serum NGF and/or no systemic AEs. Taken 
24
458 together, these PK and immunogenicity results suggest unlikely systemic absorption or 459 accumulation of topical ophthalmic rhNGF.460461 NK is a challenging disease with a high unmet need for treatments that improve corneal 462 sensitivity (which is crucial for restoring corneal epithelial integrity) and promote healing 463 without surgery or compromising vision. In the present study, topical rhNGF demonstrated 464 favorable benefit/risk ratios for patients with mild-to-moderate NK, confirming that rhNGF 465 is a feasible approach to treating NK. The neuroprotective effects of rhNGF may be also 466 extended to other ophthalmic indications with neurodegenerative components, including 467 glaucoma,21 macular degeneration,22 and retinitis pigmentosa.23468
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473 Figure Legends474475 Figure 1. REPARO phase II study design and overall patient disposition.476 The REPARO phase II study enrolled 156 patients with neurotrophic keratitis (NK) of 477 severity stage 2 (persistent epithelial defect) or stage 3 (corneal ulcer). Patients were 478 randomized 1:1:1 to 10 μg/ml rhNGF, 20 μg/ml rhNGF, or vehicle, and received 8 weeks of 479 controlled treatment and 48 weeks of follow-up. A 56-week follow-up period was intended 480 for vehicle-treated patients who experienced treatment failure (see text for details), and 481 included 8 weeks of uncontrolled treatment with 10 or 20 μg/ml rhNGF (dosage assigned 482 at baseline in a secondary randomization scheme) before continuing follow-up for 48 483 weeks.484485 Figure 2. Assessment of corneal lesion size on clinical pictures.486 A) Representative images showing the progression of a typical oval, paracentral 487 neurotrophic corneal lesion from baseline through week 8 in a patient treated with rhNGF 488 20µg/ml. Top row: pictures of the cornea illuminated with diffuse white light. Bottom row: 489 corneal lesion healed at week 8 as assessed by the central reading center on fluorescein 490 staining (green) pictures taken under cobalt-blue light illumination. B) Post hoc analysis of 491 least squares mean (LSMean) percentage change from baseline in maximum dimension of 492 persistent epithelial defect (PED) or corneal ulcer after the 8-week controlled treatment 493 period. Error bars represent standard error (SE). Magnitude change in lesion size was 494 greater in patients in the rhNGF treatment groups compared to the vehicle group (not 
26
495 reaching statistical significance), with a trend towards significance in rhNGF 20 μg/ml vs. 496 vehicle treatment at week 8 (p=0.102, 95% CI -109.61–9.98).497498 Figure 3. Secondary efficacy analysis of visual acuity score during controlled treatment. 499 Least squares mean (LSmean) change from baseline in best corrected distance visual acuity 500 (BCDVA) measured in Early Treatment Diabetic Retinopathy Study (ETDRS) letters was 501 analyzed using an analysis of covariance (ANCOVA) model (treatment + baseline score). 502 Compared to vehicle-treated patients, LSmean change from baseline to week 8 was greater 503 in the rhNGF-treated groups, with the difference reaching statistical significance in 504 between patients receiving vehicle and rhNGF 10 μg/ml (p=0.022) but not rhNGF 20 μg/ml 505 (p=0.213). However, the comparison between rhNGF doses was also not significant 506 (0.305).507508 Figure 4 (online). Exploratory analysis of change in reflex tearing during controlled 509 treatment. 510 Least squares mean (LSmean) change from baseline in Schirmer wetting distance (cm) at 5 511 minutes was analyzed using a mixed effects repeated measures model (treatment + visit + 512 treatment x visit interaction + baseline measurement). Compared to vehicle-treated 513 patients, LSmean change from baseline was greater in the rhNGF-treated groups, with 514 differences reaching statistical significance between rhNGF 10 μg/ml and vehicle groups at 515 week 4 (p=0.047) and week 8 (p=0.010). Comparisons between patients receiving rhNGF 516 20 μg/ml and vehicle were not significant at week 4 (p=0.234) or week 8 (p=0.201). 
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517 However, comparisons between rhNGF doses were also not significant at either week 4 518 (p=0.442) or week 8 (p=0.191). Error bars represent standard error (SE).519520 Figure 5. Exploratory analyses of Kaplan-Meier time-to-event variables during controlled 521 treatment. Top panel: Time to onset of healing (>20% reduction in maximum diameter of 522 the corneal lesion from baseline). Lower panel: Time to corneal healing (<0.5 mm lesion 523 staining). See text for details.524525 Figure 6 (online). Exploratory analyses of Kaplan-Meier time-to-event variables during 526 uncontrolled treatment.527 Of patients receiving vehicle during the controlled treatment period, 23 experienced 528 treatment failure and received 8 weeks of uncontrolled treatment with rhNGF 10 µg/ml or 529 20 µg/ml (see text for details). Top panel: time to onset of healing (>20% reduction in 530 maximum diameter of the corneal lesion from last measurement of the controlled 531 treatment period). All patients showed signs of healing (i.e., none were censored). Lower 532 panel: time to corneal healing (<0.5 mm lesion staining).533534 Figure 7 (online). REPARO Phase II Pharmacokinetics.535 Serum concentration of nerve growth factor (NGF) plotted over time for patients in the 536 REPARO Phase II study. Blood samples were taken prior to the initial daily dose for PK 537 profiling from approximately the first 90 patients receiving recombinant human NGF 538 (rhNGF) or vehicle, at various time points during the 8-week controlled treatment period 539 (day 1, week 1, week 3, week 6, and week 8). The lower limit of quantification (LLQ) was 
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540 32.000 pg/mL; concentrations <LLQ are considered as 0 pg/mL for the purpose of these 541 plots. A total of 5 patients had NGF concentrations >LLQ and are depicted in this figure. In 542 the rhNGF 10 μg/ml group (●), 3 patients had measurable serum NGF concentrations: 1 543 patient at day 0 (6750.7 pg/ml) and at week 8 (728.6 pg/ml), and 2 patients had 544 concentrations >LLQ at all time points. In the rhNGF 20 μg/ml group (◇), 1 had NGF 545 concentrations >LLQ at day 0, week 1, and week 3; 1 patient had NGF concentrations >LLQ 546 at weeks 1 and 3. In the vehicle group (not shown), no patients had detectable serum NGF 547 at any time point tested.
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Assessed for eligibility
(N=186)
rhNGF 10 g/ml 
(N=52)
• Received controlled 
treatment (n=52)
• Withdrew on or before 
week 8 (n=7)
o Adverse event (n=3)
o Inadequate efficacy / 
control of NK (n=2)
o Decision unrelated to 
adverse event (n=1)
o Other (n=1)
• Completed 8 weeks of 
controlled treatment 
(n=45)                                                                                                
Randomized 1:1:1 at baseline
(N=156)
rhNGF 20 g/ml
(N=52)
• Received controlled 
treatment (n=52)
• Withdrew on or before 
week 8 (n=13)
o Adverse event (n=9)
o Inadequate efficacy / 
control of NK (n=1)
o Decision unrelated to 
adverse event (n=1)
o Other (n=2)
• Completed 8 weeks of 
controlled treatment 
(n=39)                                                           
Vehicle control
(N=52)
• Received controlled 
treatment (n=52)
• Withdrew on or before 
week 8 (n=4)
o Adverse event (n=1)
o Inadequate efficacy / 
control of NK (n=0)
o Decision unrelated to 
adverse event (n=1)
o Other (n=2)
• Completed 8 weeks of 
controlled treatment 
(n=48)                                                           
rhNGF 10 g/ml 
(N=10)
• Received uncontrolled 
treatment (n=10)
• Withdrew on or before 
week 16 (n=1)
o Adverse event (n=0)
o Inadequate efficacy / 
control of NK (n=1)
o Decision unrelated to 
adverse event (n=0)
o Other (n=0)
• Completed 8 weeks of 
uncontrolled treatment 
(n=9)                                                                 
Entered 48-week follow-up 
(N=45)
• Withdrew during follow-up 
period (n=12)
o Adverse event (n=6)
o Lost to follow-up (n=4)
o Other (n=2)
• Completed 48 weeks of 
follow-up (n=33)                                                                                                
Entered 48-week follow-up 
(N=39)
• Withdrew during follow-up 
period (n=6)
o Adverse event (n=0)
o Lost to follow-up (n=2)
o Other (n=4)
• Completed 48 weeks 
follow-up (n=33)                                                           
Entered 48-week follow-up 
(N=25)
• Withdrew during follow-up 
period (n=3)
o Adverse event (n=1)
o Lost to follow-up (n=1)
o Other (n=1)
• Completed 48-week 
follow-up (n=22)                                                           
Continued follow-up 
(N=9)
• Withdrew during follow-up 
period (n=2)
o Adverse event (n=0)
o Lost to follow-up (n=0)
o Other (n=2)
• Completed 56 weeks of 
follow-up (n=7)                                                                 
Analysis population
(N=52)
• Intention-to-treat (n=52)
• Safety (n=52)
Analysis population
(N=52)
• Intention-to-treat (n=52)
• Safety (n=52)                                                                                                
Analysis population
(N=52)
• Intent-to-treat (n=52)
• Safety (n=52)
Analysis population
(N=10)
• Intention-to-treat (n=10)
• Safety (n=10)
rhNGF 20 g/ml 
(N=13)
• Received uncontrolled 
treatment (n=13)
• Withdrew on or before 
week 16 (n=0)
o Adverse event (n=0)
o Inadequate efficacy / 
control of NK (n=0)
o Other (n=0)
• Decision unrelated to 
adverse event (n=0)
• Completed 8 weeks of 
uncontrolled treatment 
(n=13)                                                                                                
Continued follow-up 
(N=13)
• Withdrew during follow-up 
period (n=4)
o Adverse event (n=0)
o Lost to follow-up (n=1)
o Other (n=3)
• Completed 56 weeks of 
follow-up (n=9)                                                                                                
Analysis population
(N=13)
• Intention-to-treat (n=13)
• Safety (n=13)
 Treatment failure during controlled vehicle treatment*
(N=23)
Randomized at week 8 / entered 56-week follow-up
(N=23)
Ineligible
(N=12)
Phase I
(N=18)
 Phase II
(N=156)
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Table 1. Patient demographics and baseline characteristics. 
Characteristics rhNGF 10 μg/ml(N=52)
rhNGF 20 μg/ml
(N=52)
Vehicle
(N=52)
Age (years)
Mean (SD) 59.0 (17.17) 62.5 (14.01) 60.4 (16.78)
Median (min, max) 61.5 (20, 87) 63.5 (18, 95) 60.5 (23, 91)
Female, n (%) 30 (57.7) 30 (57.7) 35 (67.3)
Ethnicity, n (%)
Hispanic, Latino, or Spanish 6 (11.5) 9 (17.3) 5 (9.6)
N/A 4 (7.7) 1 (1.9) 6 (11.5)
Race, n (%)
Asian 1 (1.9) 0 1 (1.9)
Black or African American 0 0 1 (1.9)
White 46 (88.5) 51 (98.1) 45 (86.5)
N/A 5 (9.6) 1 (1.9) 5 (9.6)
Primary NK diagnosis, n (%)
Stage 2 21 (40.4) 27 (51.9) 28 (53.8)
Stage 3 31 (59.6) 25 (48.1) 24 (46.2)
Diabetes mellitus 3 (5.8) 4 (7.7) 4 (7.7)
Underlying etiology, n (%)
Dry eye disease 6 (11.5) 6 (11.5) 5 (9.6)
Herpetic eye disease* 15 (28.8) 11 (21.2) 18 (34.6)
Neurosurgical procedure
Acoustic neuroma 2 (3.8) 1 (1.9) 3 (5.8)
Auditive neurosurgery 0 1 (1.9) 0
Cerebellar metastasis 0 1 (1.9) 0
Cerebral epidermoid cyst aspiration 0 1 (1.9) 0
Craniotomy due to glioma 1 (1.9) 0 0
Facial nerve reconstruction 1 (1.9) 0 0
Meningioma excision 0 1 (1.9) 1 (1.9)
Schwannoma 1 (1.9) 1 (1.9) 3 (5.8)
Unspecified 1 (1.9) 2 (3.8) 0
Nonviral infection
Amoebic keratitis 0 2 (3.8) 0
Unspecified 1 (1.9) 0 1 (1.9)
Ocular surface injury / inflammation
Chemical burn 4 (7.7) 2 (3.8) 3 (5.8)
Unspecified 1 (1.9) 3 (5.8) 2 (3.8)
Ocular surgery or procedure
Cataract surgery/scleral buckle/vitrectomy 1 (1.9) 1 (1.9) 1 (1.9)
Corneal transplantation 0 0 1 (1.9)
Keratoplasty 2 (3.8) 0 0
Maxillofacial surgery (eyelid suture) 1 (1.9) 0 0
Strontium brachytherapy, mitomycin drops 0 0 1 (1.9)
Unspecified 5 (9.6) 4 (7.7) 4 (7.7)
Other
Atopic dermatitis 1 (1.9) 0 0
Corneal hypoesthesia 0 1 (1.9) 0
Facial palsy due to measles 1 (1.9) 0 0
Goldenhar syndrome 0 0 1 (1.9)
Graves-Basedow disease 0 1 (1.9) 0
Lagophthalmos 0 0 1 (1.9)
Miller-Fisher syndrome 1 (1.9) 0 0
Multifactorial (HSV, keratoplasty, burn, diabetes) 0 1 (1.9) 0
Neurovascular encephalopathy 0 1 (1.9) 0
Paraneoplastic neuropathy (lung cancer) 0 1 (1.9) 0
Pemphigoid 0 1 (1.9) 1 (1.9)
Polyneuropathy, traumatic erosion 0 1 (1.9) 0
Stroke 1 (1.9) 2 (3.8) 0
Systemic medication 1 (1.9) 0 0
Topical medication (glaucoma medication) 0 1 (1.9) 1 (1.9)
Unknown origin 1 (1.9) 1 (1.9) 0
Venous sinus thrombosis 1 (1.9) 0 0
Viral conjunctivitis (unspecified) 0 0 1 (1.9)
Abbreviations: HSV = herpes simplex virus; min= minimum; max = maximum; N/A: not available (ethnicity and race were not 
collected in all countries); rhNGF = recombinant human nerve growth factor; SD = standard deviation
*Includes herpes simplex, herpes zoster, and recurrent herpetic keratitis
Table 2. Primary efficacy analysis of corneal healing (<0.5 mm lesion staining).
rhNGF 10 μg/ml
(N=52)
rhNGF 20 μg/ml
(N=52)
Vehicle
(N=52)
Healed at week 4, n (%) 28/51 (54.9) 29/50 (58.0) 10/51 (19.6)
Difference (rhNGF - vehicle), % 35.3 38.4
97.06% CI 15.88, 54.71 18.96, 57.83
p-value <0.001 <0.001
Difference (rhNGF20 μg/ml - rhNGF10 μg/ml), % 3.1
97.06% CI -18.38, 24.58
p-value 0.754
Healed at week 8, n (%) 38/51 (74.5) 37/50 (74.0) 22/51 (43.1)
Difference (rhNGF - vehicle), % 31.4 30.9
97.06% CI 11.25, 51.49 10.60, 51.13
p-value 0.001 0.002
Difference (rhNGF20 μg/ml - rhNGF10 μg/ml), % -0.5
97.06% CI -19.46, 18.44
p-value 0.953
Abbreviations: CI = confidence interval; µg = microgram; ml = milliliter; N = number of patients randomized to 
each treatment; rhNGF = recombinant human nerve growth factor
Table 3. Post hoc efficacy analysis of corneal healing (0 mm lesion staining, no other 
persistent staining).
rhNGF 10 μg/ml
(N=52)
rhNGF 20 μg/ml
(N=52)
Vehicle
(N=52)
Healed at week 4, n (%) 25/51 (49) 29/50 (58) 7/51 (13.7)
Difference (rhNGF - vehicle), % 35.3 44.3
97.06% CI 16.78, 53.80 25.80, 62.75
p-value <0.001 <0.001
Difference (rhNGF20 μg/ml - rhNGF10 μg/ml), % 9.0
97.06% CI -12.55, 30.51
p-value 0.366
Healed at week 8, n (%) 32/51 (62.7) 36/50 (72.0) 17/51 (33.3)
Difference (rhNGF - vehicle), % 29.4 38.7
97.06% CI 8.82, 50.01 18.72, 58.62
p-value 0.003 <0.001
Difference (rhNGF20 μg/ml - rhNGF10 μg/ml), % 9.3
97.06% CI -10.96, 29.47
p-value 0.321
Abbreviations: CI = confidence interval; µg = microgram; ml = milliliter; N = number of patients randomized to 
each treatment; rhNGF = recombinant human nerve growth factor
Table 4. Secondary efficacy analysis of patients achieving 15-letter gains in BCDVA
rhNGF 10 μg/ml
(N=52)
rhNGF 20 μg/ml
(N=52)
Vehicle
(N=52)
15-letter gain in BCDVA at week 4, n (%) 18/49 (36.7) 14/41 (34.1) 9/43 (20.9)
Difference (rhNGF - vehicle), % 15.8 13.2
95% CI -2.36, 33.97 -5.72, 32.15
p-value 0.097 0.175
Difference (rhNGF20 μg/ml - rhNGF10 μg/ml), % -2.6
95% CI -22.41, 17.23
p-value 0.798
15-letter gain in BCDVA at week 8, n (%) 24/48 (50.0) 17/41 (41.5) 9/40 (22.5)
Difference (rhNGF - vehicle), % 27.5 19.0
95% CI 8.33, 46.67 -0.91, 38.83
p-value 0.008 0.068
Difference (rhNGF20 μg/ml - rhNGF10 μg/ml), % -8.5
95% CI -29.21, 12.14
p-value 0.421
BCDVA = best corrected distance visual acuity; CI = confidence interval; µg = microgram; ml = milliliter; N = 
number of patients randomized to each treatment; rhNGF = recombinant human nerve growth factor.
Patients without a Yes/No response available at Week 4/Week 8 are not considered in this table. The significance 
level is 0.05.
Table 5. Secondary efficacy analysis of improved corneal sensitivity 
during controlled treatment. 
 rhNGF 10 µg/ml (N=52) 
rhNGF 20 µg/ml 
(N=52) 
Vehicle 
(N=52) 
Improvement in corneal sensitivity at week 4, n (%) 31/45 (68.9) 22/36 (61.1) 26/41 (63.4) 
Difference (rhNGF - vehicle), % 5.5 -2.3  
95% CI -14.53, 25.48 -24.01, 19.40  
p-value 0.592 0.835  
Difference (rhNGF20 µg/ml - rhNGF10 µg/ml), % -7.8   
95% CI -28.67, 13.12   
p-value 0.465   
Improvement in corneal sensitivity at week 8, n (%) 33/42 (78.6) 29/38 (76.3) 26/38 (68.4) 
Difference (rhNGF - vehicle), % 10.2 7.9  
95% CI -9.15, 29.45 -12.13, 27.92  
p-value 0.303 0.442  
Difference (rhNGF20 µg/ml - rhNGF10 µg/ml), % -2.3   
95% CI -20.61, 16.09   
p-value 0.809   
 
CI = confidence interval; µg = microgram; ml = milliliter; N = number of patients randomized to each treatment; 
rhNGF = recombinant human nerve growth factor 
Patients without a Yes/No response available at Week 4/Week 8 are not considered in this table. The significance 
level is 0.05. 
 
Table 6. Summary of treatment-related adverse events* by system organ class and 
preferred term (controlled treatment period). 
Body System 
MedDRA Preferred Term§
rhNGF 10 μg/ml
(N=52)
rhNGF 20 μg/ml
(N=52)
Vehicle
(N=52)
N’ n (%) N’ n (%) N’ n (%)
Any adverse event 10 6 (11.5) 15 9 (17.3) 20 10 (19.2)
Eye disorders 7 5 (9.6) 10 7 (13.5) 16 9 (17.3)
Eye pain 0 0 4 4 (7.7) 3 2 (3.8)
Blepharitis 1 1 (1.9) 1 1 (1.9) 1 1 (1.9)
Corneal neovascularization 0 0 1 1 (1.9) 1 1 (1.9)
Eye irritation 1 1 (1.9) 0 0 1 1 (1.9)
Eye pruritus 0 0 1 1 (1.9) 1 1 (1.9)
Vision blurred 0 0 0 0 2 2 (3.8)
Abnormal sensation in eye 0 0 0 0 1 1 (1.9)
Asthenopia 0 0 0 0 1 1 (1.9)
Conjunctival hyperemia 0 0 0 0 1 1 (1.9)
Corneal deposits 0 0 1 1 (1.9) 0 0
Corneal epithelium defect 0 0 0 0 1 1 (1.9)
Dry eye 0 0 0 0 1 1 (1.9)
Eye discharge 1 1 (1.9) 0 0 0 0
Eyelid edema 0 0 0 0 1 1 (1.9)
Eyelid pain 2 1 (1.9) 0 0 0 0
Lacrimation increased 1 1 (1.9) 0 0 0 0
Macular fibrosis 0 0 1 1 (1.9) 0 0
Ocular hyperemia 0 0 0 0 1 1 (1.9)
Photophobia 1 1 (1.9) 0 0 0 0
Visual acuity reduced 0 0 1 1 (1.9) 0 0
General disorders and administration site 
conditions 1 1 (1.9) 0 0 3 3 (5.8)
Disease progression† 1 1 (1.9) 0 0 2 2 (3.8)
Instillation site pain 0 0 0 0 1 1 (1.9)
Nervous system disorders 2 2 (3.8) 1 1 (1.9) 1 1 (1.9)
Headache 1 1 (1.9) 1 1 (1.9) 1 1 (1.9)
Neuralgia 1 1 (1.9) 0 0 0 0
Blood and lymphatic system disorders 0 0 1 1 (1.9) 0 0
Neutropenia 0 0 1 1 (1.9) 0 0
Cardiac disorders 0 0 1 1 (1.9) 0 0
Arrhythmia 0 0 1 1 (1.9) 0 0
Infections and infestations 0 0 1 1 (1.9) 0 0
Corneal abscess 0 0 1 1 (1.9) 0 0
Investigations 0 0 1 1 (1.9) 0 0
Blood pressure increased 0 0 1 1 (1.9) 0 0
Abbreviations: AE = adverse event; MedDRA = Medical Dictionary for Regulatory Activities; N = number of 
patients who received each treatment in the specified study period; N’ = number of events reported, n = number of 
patients; rhNGF = recombinant human nerve growth factor.
Percentages (%) are calculated using the population number in each treatment group (N) as the denominator.
*Treatment-related AEs are those events recorded by the investigator as having a possible, probable, or highly 
probable relationship to study treatment. 
† Disease progression was defined as increase in lesion size ≥ 1mm; decrease in best corrected distance visual acuity 
(BCDVA) by >5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters; progression in lesion depth to 
corneal melting or perforation; or onset of infection.
Figure 4. Exploratory efficacy analysis of change in reflex tearing 
during the controlled treatment period. 
Least squares mean (LSmean) change from baseline in Schirmer wetting distance in centimeters 
(cm) at 5 minutes was analyzed using a mixed effects repeated measures model (treatment + visit 
+ treatment x visit interaction + baseline measurement). Compared to vehicle-treated patients, 
LSmean change from baseline was greater in the rhNGF-treated groups, with differences 
reaching statistical significance between rhNGF 10 µg/ml and vehicle groups at week 4 
(p=0.047) and week 8 (p=0.010). Comparisons between patients receiving rhNGF 20 µg/ml and 
vehicle were not significant at week 4 (p=0.234) or week 8 (p=0.201). However, comparisons 
between rhNGF doses were also not significant at either week 4 (p=0.442) or week 8 (p=0.191). 
Error bars represent standard error (SE). 
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Figure 6. Exploratory analyses of Kaplan-Meier time-to-event variables 
during uncontrolled treatment. 
Of patients receiving vehicle during the controlled treatment period, 23 experienced treatment failure 
and received 8 weeks of of uncontrolled treatment with rhNGF 10 µg/ml or 20 µg/ml (see text for 
details). Top panel: time to onset of healing (>20% reduction in maximum diameter of the corneal lesion 
from last measurement of the controlled treatment period). All patients showed signs of healing (i.e., 
none were censored). Lower panel: time to corneal healing (<0.5 mm lesion staining). 
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	Figure 7. REPARO Phase II Pharmacokinetics. 
Serum concentration of nerve growth factor (NGF) plotted over time for patients in the REPARO 
Phase II study. Blood samples were taken prior to the initial daily dose for PK profiling from 
approximately the first 90 patients receiving recombinant human NGF (rhNGF) or vehicle, at 
various time points during the 8-week controlled treatment period (day 1, week 1, week 3, week 
6, and week 8). The lower limit of quantification (LLQ) was 32.000 pg/mL; concentrations 
<LLQ are considered as 0 pg/mL for the purpose of these plots. A total of 5 patients had NGF 
concentrations >LLQ and are depicted in this figure. In the rhNGF 10 µg/ml group (●), 3 patients 
had measurable serum NGF concentrations: 1 patient at day 0 (6750.7 pg/ml) and at week 8 
(728.6 pg/ml), and 2 patients had concentrations >LLQ at all time points. In the rhNGF 20 µg/ml 
group (), 1 had NGF concentrations >LLQ at day 0, week 1, and week 3; 1 patient had NGF 
concentrations >LLQ at weeks 1 and 3. In the vehicle group (not shown), no patients had 
detectable serum NGF at any time point tested. 	
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Appendix	2.	REPARO Phase II Study: Complete Eligibility	Criteria	
	
Inclusion	Criteria	Individuals	who	met	all	of	the	following	conditions	were	eligible	for	enrollment	in	this	study:	1. Patients	18	years	of	age	or	older.	2. Patients	with	Stage	2	PED	or	Stage	3	(corneal	ulcer)	neurotrophic	keratitis	involving	only	1	eye.		Patients	with	contralateral	eye	affected	with	Stage	1	NK	could	be	enrolled.	3. PED	or	corneal	ulceration	of	at	least	2	weeks	duration	refractory	to	one	or	more	conventional	non-surgical	treatments	for	neurotrophic	keratitis	(eg,	preservative-free	artificial	tears,	gels	or	ointments;	discontinuation	of	preserved	topical	drops	and	medications	that	can	decrease	corneal	sensitivity;	therapeutic	contact	lenses).			4. Evidence	of	decreased	corneal	sensitivity	(≤	4	cm	using	the	Cochet-Bonnet	aesthesiometer)	within	the	area	of	the	PED	or	corneal	ulcer	and	outside	of	the	area	of	the	defect	in	at	least	1	corneal	quadrant.			5. Best	corrected	distance	visual	acuity	(BCDVA)	score	≤	75	Early	Treatment	Diabetic	Retinopathy	Study	(ETDRS)	letters,	(≥	+	0.2	LogMAR,	≤	20/32	Snellen	or	≤	0.625	decimal	fraction)	in	the	affected	eye.			6. No	objective	clinical	evidence	of	improvement	in	the	PED	or	corneal	ulceration	within	the	2	weeks	prior	to	study	enrolment.	7. Only	patients	who	satisfied	all	Informed	Consent	requirements	could	be	included	in	the	study.		The	patient	and/or	his/her	legal	representative	must	have	read,	signed	and	dated	the	Informed	Consent	document	before	any	study-related	procedures	were	performed.		
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The	Informed	Consent	form	signed	by	patients	and/or	legal	representative	must	have	been	approved	by	the	IEC/IRB	for	the	current	study.	8. Patients	must	have	had	the	ability	and	willingness	to	comply	with	study	procedures.	Patients	must	have	been	eligible	for	the	National	Health	Insurance	(where	applicable).	
Exclusion	Criteria	Individuals	who	met	any	of	the	following	conditions	were	excluded	from	this	study:	1. Patients	with	Stage	2	or	3	NK	affecting	both	eyes.	2. Any	active	ocular	infection	(bacterial,	viral,	fungal	or	protozoal)	or	active	ocular	inflammation	not	related	to	NK	in	the	affected	eye.			3. Any	other	ocular	disease	requiring	topical	ocular	treatment	in	the	affected	eye	during	the	course	of	the	study	treatment	period.		No	topical	treatments	other	than	the	study	medications	provided	by	the	study	sponsor	or	allowed	by	the	study	protocol	could	be	administered	in	the	affected	eye	during	the	course	of	the	study	treatment	periods.			4. Patients	with	severe	vision	loss	in	the	affected	eye	with	no	potential	for	visual	improvement	in	the	opinion	of	the	Investigator	as	a	result	of	the	study	treatment.	5. Schirmer	test	without	anesthesia	≤	3	mm/5	minutes	in	the	affected	eye.	6. Patients	with	severe	blepharitis	and/or	severe	meibomian	gland	disease	in	the	affected	eye.	7. History	of	any	ocular	surgery	(including	laser	or	refractive	surgical	procedures)	in	the	affected	eye	within	the	three	months	before	study	enrolment.		(An	exception	to	the	preceding	statement	was	allowed	if	the	ocular	surgery	was	considered	to	be	the	cause	of	the	Stage	2	or	3	NK).		Ocular	surgery	in	the	affected	eye	was	not	allowed	during	the	study	
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treatment	period	and	elective	ocular	surgery	procedures	should	not	have	been	planned	during	the	duration	of	the	follow-up	period.	8. Prior	surgical	procedure(s)	for	the	treatment	of	NK	(eg,	complete	tarsorraphy,	conjunctival	flap,	etc)	in	the	affected	eye	with	the	exception	of	amniotic	membrane	transplantation.		Patients	previously	treated	with	amniotic	membrane	transplantation	could	only	be	enrolled	2	weeks	after	the	membrane	had	disappeared	within	the	area	of	the	PED	or	corneal	ulcer	or	at	least	6	weeks	after	the	date	of	the	amniotic	membrane	transplantation	procedure.		Patients	previously	treated	with	Botox	(botulinum	toxin)	injections	used	to	induce	pharmacologic	blepharoptosis	were	eligible	for	enrolment	only	if	the	last	injection	was	given	at	least	90	days	prior	to	enrolment	in	the	study.			9. Use	of	therapeutic	contact	lenses	or	contact	lens	wear	for	refractive	correction	during	the	study	treatment	periods	in	the	eye	with	NK.	10. Anticipated	need	for	punctual	occlusion	during	the	study	treatment	period.		Patients	with	punctual	occlusion	or	punctual	plugs	inserted	prior	to	the	study	were	eligible	for	enrolment	provided	that	the	punctual	occlusion	was	maintained	during	the	study.			11. Evidence	of	corneal	ulceration	involving	the	posterior	third	of	the	corneal	stroma,	corneal	melting	or	perforation	in	the	affected	eye.			12. Presence	or	history	of	any	ocular	or	systemic	disorder	or	condition	that	might	have	hindered	the	efficacy	of	the	study	treatment	or	its	evaluation,	could	possibly	have	interfered	with	the	interpretation	of	study	results,	or	could	have	been	judged	by	the	Investigator	to	be	incompatible	with	the	study	visit	schedule	or	conduct	(eg,		progressive	or	degenerative	corneal	or	retinal	conditions,	uveitis,	optic	neuritis,	poorly	controlled	diabetes,	autoimmune	disease,	systemic	infection,	neoplastic	diseases).	
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13. Any	need	for	or	anticipated	change	in	the	dose	of	systemic	medications	known	to	impair	the	function	of	the	trigeminal	nerve	(eg,	neuroleptics,	antipsychotic	and	antihistamine	drugs).		These	treatments	were	allowed	during	the	study	if	initiated	prior	to	30	days	before	study	enrolment	provided	they	remained	stable	throughout	the	course	of	the	study	treatment	periods.	14. Known	hypersensitivity	to	one	of	the	components	of	the	study	or	procedural	medications	(eg,	fluorescein).	15. History	of	drug,	medication	or	alcohol	abuse	or	addiction.	16. Use	of	any	investigational	agent	within	4	weeks	of	Baseline	visit.	17. Participation	in	another	clinical	study	at	the	same	time	as	the	present	study.	18. Females	of	childbearing	potential	(those	who	are	not	surgically	sterilized	or	post-menopausal	for	at	least	1	year)	were	excluded	from	participation	in	the	study	if	they	met	any	1	of	the	following	conditions:	a. were	currently	pregnant	or,	b. had	a	positive	result	on	the	urine	pregnancy	test	at	the	Randomization	Visit	or,	c. intended	to	become	pregnant	during	the	study	treatment	period	or,	d. were	breast-feeding	or,	e. not	willing	to	use	highly	effective	birth	control	measures,	such	as:	Hormonal	contraceptives	–oral,	implanted,	transdermal,	or	injected	and/or	Mechanical	barrier	methods	–spermicide	in	conjunction	with	a	barrier	such	as	a	condom	or	diaphragm	or	intra-uterine	device	(IUD)	during	the	entire	course	of	and	30	days	after	the	study	treatment	periods.	
Appendix 3. REPARO phase II study: prior treatments for neurotrophic keratitis 	
Treatment, n (%) 
rhNGF 
10 µg/ml 
(N=52) 
rhNGF 
20 µg/ml 
(N=52) 
Vehicle 
Control 
(N=52) 
Total 
 
(N=156) 
Artificial tears/gels/ointments 24 (46.2) 29 (55.8) 26 (50.0) 79 (50.6) 
Preservative free artificial tears/gels/ointments 27 (51.9) 20 (38.5) 24 (46.2) 71 (45.5) 
Topical antibiotics 30 (57.7) 32 (61.5) 33 (63.5) 95 (60.9) 
Discontinuation of topical medications 0 2 (3.8) 0 2 (1.3) 
Therapeutic contact lens 13 (25.0) 23 (44.2) 11 (21.2) 47 (30.1) 
Anti-cholinergic agents 7 (13.5) 2 (3.8) 4 (7.7) 13 (8.3) 
Autologous serum eye drops 4 (7.7) 5 (9.6) 5 (9.6) 14 (9.0) 
Botulinum a toxin injections 2 (3.8) 1 (1.9) 2 (3.8) 5 (3.2) 
Cyanoacrylate glue 2 (3.8) 0 0 2 (1.3) 
Collagenase inhibitors 1 (1.9) 0 2 (3.8) 3 (1.9) 
Tarsorraphy 2 (3.8) 2 (3.8) 1 (1.9) 5 (3.2) 
Conjunctival flap procedure 0 1 (1.9) 0 1 (0.6) 
Amniotic membrane transplantation  4 (7.7) 5 (9.6) 3 (5.8) 12 (7.7) 
Other  18 (34.6) 20 (38.5) 28 (53.8) 66 (42.3) 
 
Abbreviations: rhNGF = recombinant human nerve growth factor 
Percentages are calculated using the population number in each treatment group as the denominator. 
Patients may be counted under more than one category.  
 
Appendix 4. REPARO Phase II Study: Additional Safety Results 
 
Treatment-related adverse events (TAEs) 
 
Controlled treatment period  
 
See text. 
 
Uncontrolled treatment period  
 
Overall, 4 patients (17.4%) reported 8 treatment-related AEs during the uncontrolled treatment period in 
the phase II segment of the study: 2 patients (20.0%) in the rhNGF 10 µg/ml group and 2 patients 
(15.4%) in the rhNGF 20 µg/ml group.  Six of the 8 treatment related AEs were in the class of eye 
disorders (all in the rhNGF 20 µg/ml group), 1 treatment-related AE was disease progression (rhNGF 10 
µg/ml group), and 1 treatment-related AE was increased blood creatinine (rhNGF 10 µg/ml group). 
 
Follow-up period 
 
Overall, 2 patients (1.3%) reported 3 treatment-related AEs during the follow-up period in the phase II 
segment of the study: 1 patient in the rhNGF 10 µg/ml group experienced a treatment-related AE of vital 
dye staining cornea present, and 1 patient in the vehicle control group had treatment-related AEs of dry 
eye and eyelid pain. 
 
Serious adverse events (SAEs) leading to death 
 
Controlled treatment period 
 
Two patients experienced SAEs of malignant neoplasm progression leading to death during the 
controlled treatment period: One patient receiving rhNGF 10 µg/ml died due to evolution of squamous 
cell carcinoma, and one patient receiving rhNGF 20 µg/ml group died due to lung cancer progression. 
Neither death was considered by the investigator to be related to study treatment.  
 
Uncontrolled treatment period 
 
No deaths occurred during the uncontrolled treatment period. 
 
Follow-up period 
 
Six patients experienced SAEs leading to death during the follow-up period: four patients who received 
rhNGF 10 µg/ml (cardiac failure; myocardial infarction; arrhythmia and dyspnea; and aortic dissection, 
aortic rupture, and hemorrhagic shock), one patient who received rhNGF 20 µg/ml (respiratory failure), 
and one patient who received vehicle (respiratory failure). All deaths were considered unrelated to study 
treatment. 
